However, the above-mentioned IFNβ-related modifications in adaptive markers were not perceived in a subgroup of MS patients prospectively followed after 1 year of treatment (Supplementary Figure 2), indicating that the cytokine does not directly modify the adaptive NK cell immunophenotype. This evidence concerns the gene IFNB1 and myeloid sarcoma.